Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Novel targeted therapeutics against acute myeloid leukemia stem cells

FY 2018-19

Summary
Acute myeloid leukemia (AML) is an aggressive form of blood cancer defined by the accumulation of abnormal blood cells in the blood and bone marrow. In our bodies, blood cells have a limited lifespan and need to be continuously replaced by hematopoietic stem cells (HSCs). This process is disrupted in patients with AML and leads to hematopoietic failure. Therapy for AML exists, however the standard drugs have not changed in the last 30 years and involve intensive and aggressive treatments. Although most patients respond to therapy, many relapse with a more aggressive form of the disease. Currently, up to 70% of adults and 30% of children do not survive beyond 5 years post-diagnosis due to treatment failure or relapse. This is partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that evade treatment. To improve safety and efficacy, novel therapies need to preferentially target LSCs while sparing HSCs, however this is difficult as both cell types share similar biological characteristics. Through the use of established HSC and LSC gene signatures, our lab identified 12 compounds that can preferentially target LSCs while sparing HSCs in vitro. Our next step is to establish the preclinical usefulness of these compounds to understand how the LSCs are impacted, their biological targets in the body and toxicities. This will help establish better treatment plans to reduce relapse rate and increase patient survival. Finally, we aim to investigate their mechanisms of action to yield insight on the biology of these stem cells. Since most of these compounds have been FDA approved and are being used to treat other diseases, they have a high potential to be used in the clinical, thus accelerating regulatory approval and reducing costs for drug discovery.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
416075
Name
Iasenza Isabella A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel targeted therapeutics against acute myeloid leukemia stem cells
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Biochemistry; Hematology; Hematopoietic Stem Cells; Leukemic Stem Cells; Medicinal Chemistry; Molecular Mechanisms; Oncology; Pathogenesis; Stem Cell Biology
Abstract
Acute myeloid leukemia (AML) is an aggressive form of blood cancer defined by the accumulation of abnormal blood cells in the blood and bone marrow. In our bodies, blood cells have a limited lifespan and need to be continuously replaced by hematopoietic stem cells (HSCs). This process is disrupted in patients with AML and leads to hematopoietic failure. Therapy for AML exists, however the standard drugs have not changed in the last 30 years and involve intensive and aggressive treatments. Although most patients respond to therapy, many relapse with a more aggressive form of the disease. Currently, up to 70% of adults and 30% of children do not survive beyond 5 years post-diagnosis due to treatment failure or relapse. This is partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that evade treatment. To improve safety and efficacy, novel therapies need to preferentially target LSCs while sparing HSCs, however this is difficult as both cell types share similar biological characteristics. Through the use of established HSC and LSC gene signatures, our lab identified 12 compounds that can preferentially target LSCs while sparing HSCs in vitro. Our next step is to establish the preclinical usefulness of these compounds to understand how the LSCs are impacted, their biological targets in the body and toxicities. This will help establish better treatment plans to reduce relapse rate and increase patient survival. Finally, we aim to investigate their mechanisms of action to yield insight on the biology of these stem cells. Since most of these compounds have been FDA approved and are being used to treat other diseases, they have a high potential to be used in the clinical, thus accelerating regulatory approval and reducing costs for drug discovery.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Iasenza, Isabella A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~